[go: up one dir, main page]

MX2016007440A - Inhibidores del bromodominio. - Google Patents

Inhibidores del bromodominio.

Info

Publication number
MX2016007440A
MX2016007440A MX2016007440A MX2016007440A MX2016007440A MX 2016007440 A MX2016007440 A MX 2016007440A MX 2016007440 A MX2016007440 A MX 2016007440A MX 2016007440 A MX2016007440 A MX 2016007440A MX 2016007440 A MX2016007440 A MX 2016007440A
Authority
MX
Mexico
Prior art keywords
bromodomain inhibitors
compounds
formula
diseases
aids
Prior art date
Application number
MX2016007440A
Other languages
English (en)
Inventor
K Pratt John
M Hansen Todd
J Mcclellan William
F Mcdaniel Keith
Liu Dachun
K Wada Carol
R Frey Robin
Wang Le
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2016007440A publication Critical patent/MX2016007440A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/153—Ortho-condensed systems the condensed system containing two rings with oxygen as ring hetero atom and one ring with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a compuestos de fórmula (I) en donde Rx, X, Y, Y1, L1, A1, A2, A3, A4, A5, A6, A7, y A8, tienen cualquiera de los valores definidos en la especificación, y sales de los mismos farmacéuticamente aceptables, que son útiles como agentes en el tratamiento de enfermedades y condiciones, que incluyen enfermedades inflamatorias, cáncer, y SIDA. También se proporcionan composiciones farmacéuticas comprendidas de uno o más compuestos de fórmula (I).
MX2016007440A 2013-12-10 2014-12-10 Inhibidores del bromodominio. MX2016007440A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNPCT/CN2013/088948 2013-12-10
PCT/CN2014/093466 WO2015085925A1 (en) 2013-12-10 2014-12-10 Bromodomain inhibitors

Publications (1)

Publication Number Publication Date
MX2016007440A true MX2016007440A (es) 2016-09-08

Family

ID=53370625

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016007440A MX2016007440A (es) 2013-12-10 2014-12-10 Inhibidores del bromodominio.

Country Status (8)

Country Link
US (1) US9994581B2 (es)
EP (1) EP3080132A4 (es)
JP (1) JP2016539990A (es)
CN (1) CN105980392A (es)
AU (1) AU2014361381A1 (es)
CA (1) CA2932040A1 (es)
MX (1) MX2016007440A (es)
WO (1) WO2015085925A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3099677A4 (en) 2014-01-31 2017-07-26 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
JP2017504651A (ja) 2014-01-31 2017-02-09 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ジアゼパン誘導体の使用
US10881668B2 (en) 2015-09-11 2021-01-05 Dana-Farber Cancer Institute, Inc. Acetamide thienotriazolodiazepines and uses thereof
CA2996974A1 (en) 2015-09-11 2017-03-16 Dana-Farber Cancer Institute, Inc. Cyano thienotriazolodiazepines and uses thereof
SG10201913450PA (en) * 2015-11-25 2020-03-30 Dana Farber Cancer Inst Inc Bivalent bromodomain inhibitors and uses thereof
MX379459B (es) 2016-04-15 2025-03-10 Abbvie Inc Inhibidores de bromodominios.
EP3609896A4 (en) * 2017-04-14 2020-11-04 AbbVie Inc. BROMODOMAIN INHIBITORS
CN110038120B (zh) * 2019-04-02 2022-12-23 河南师范大学 豹蛙抗瘤酶融合蛋白作为治疗肿瘤药物的应用
EP3970574A4 (de) 2019-05-17 2023-01-25 Severin Asia Limited Vorrichtung und verfahren zur extraktion von komponenten in feststoffen mittels nanoblasen
CN120623106A (zh) 2019-09-30 2025-09-12 协和麒麟株式会社 Bet降解剂
US12527741B2 (en) 2021-06-17 2026-01-20 Wisconsin Alumni Research Foundation Modular dendron micelles for treatment of pulmonary diseases related to fibrosis and viral infection including COVID-19
WO2023146512A1 (en) * 2022-01-25 2023-08-03 Vivace Therapeutics, Inc. Compounds and methods of use thereof
CN116003315B (zh) * 2023-01-09 2024-07-16 中国药科大学 一种双芳基醚吡啶酮类化合物及其制备方法与应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1308441B1 (en) 2000-08-11 2009-10-07 Eisai R&D Management Co., Ltd. 2-aminopyridine compounds and use thereof as drugs
EP2239264A4 (en) 2007-12-28 2012-01-11 Mitsubishi Tanabe Pharma Corp ANTITUMORAL MEDIUM
GB0919431D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919432D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
AR084070A1 (es) * 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
US9249161B2 (en) 2010-12-02 2016-02-02 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors

Also Published As

Publication number Publication date
US20170015673A1 (en) 2017-01-19
EP3080132A4 (en) 2017-08-02
AU2014361381A1 (en) 2016-06-16
JP2016539990A (ja) 2016-12-22
WO2015085925A1 (en) 2015-06-18
US9994581B2 (en) 2018-06-12
CN105980392A (zh) 2016-09-28
CA2932040A1 (en) 2015-06-18
EP3080132A1 (en) 2016-10-19

Similar Documents

Publication Publication Date Title
PH12015502004A1 (en) Tetracyclic bromodomain inhibitors
PH12015502852A1 (en) Bromodomain inhibitor
MX2015012005A (es) Inhibidores de bromodominio.
PH12018501920A1 (en) Bromodomain inhibitors
MX2016007440A (es) Inhibidores del bromodominio.
MX2015011984A (es) Inhibidores de bromodominio de dihidro-pirrolopiridinona.
MX2015012158A (es) Inhibidores de bomodominio tetraciclicos fusionados.
PH12014501469A1 (en) Bromodomain inhibitors
MX2016007346A (es) Derivados de dihidropiridinona y dihidropiridazinona utiles como inhibidores de bromodominio.
MX2015012431A (es) Pirrol amida como inhibidores.
MX2014012695A (es) Derivados de isoindolona.
PH12016501355A1 (en) Bicyclic heterocyclic derivatives as bromodomain inhibitors
IN2015DN01156A (es)
MX2018005041A (es) Compuestos para tratar la esclerosis lateral amiotrofica.
MX2020001717A (es) Inhibidores macrociclicos de mcl-1 y metodos de uso.
MD4684B1 (ro) Formulări pe bază de imidazopirazine în calitate de inhibitori SYK
MX2015010829A (es) Compuestos terapeuticos y sus usos.
MX2015016425A (es) Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades.
IN2014DN06869A (es)
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
MX2019004375A (es) Inhibidores de bromodominios.
MX2019004187A (es) Inhibidores de bromodominios.
MX2015012153A (es) Inhibidores de la quinasa pirrolopirimidina cdk9.
MX2017002544A (es) Derivados de isoquinolinona utiles en el tratamiento contra el cancer.
MX2017002627A (es) Derivados de polieteres macrociclicos de n-aril-2-amino-4-aril-pir imidina como inhibidores de ftl3 y jak.